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Purpose: This study aimed to compare complications, perioperative parameters, and oncologic outcomes between robot-assisted 
radical cystectomy (RARC) with extracorporeal urinary diversion (ECUD) and RARC with intracorporeal urinary diversion (ICUD).
Materials and Methods: Between 2007 and 2017, 362 patients who underwent RARC with ECUD or ICUD at multiple tertiary 
referral institutions were assessed. The primary endpoints were complication rates. The secondary outcomes were perioperative re-
covery parameters and oncological outcomes including estimated recurrence-free survival (RFS) and recurrence pattern between 
the 2 groups. Additionally, the complication rates of 2 expert surgeons with experience of >100 RARCs were analyzed.
Results: The ICUD group showed lower overall, gastrointestinal, and genitourinary complications (p=0.001, p=0.036, and p=0.036, 
respectively) than the ECUD group. Concerning perioperative outcomes, the ICUD group had a significantly longer operation time 
(p=0.002), although recovery parameters such as time to flatus passage, oral intake, and length of hospital stay were significantly 
shorter in this group (p=0.001, p<0.001, and p<0.001, respectively). There was no difference in oncologic outcomes such as posi-
tive margin rate (p=0.944) and 2-year RFS (p=0.496), and in the recurrence pattern between groups. In the comparison of the ex-
pert surgeons’ complication rates, the major and total complication rates did not show differences (p=0.814 and p=0.102, respec-
tively) while the minor complication rates were lower in the ICUD group (p=0.058).
Conclusions: This multi-institutional cohort study demonstrated the benefits of the ICUD approach, as indicated by lower compli-
cation rates and better recovery parameters, although the oncological results were similar to those of ECUD.
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Since its adoption in 2003, robot-assisted radical cystec-
tomy (RARC) has been steadily increasingly used worldwide, 
as a minimally invasive alternative to open radical cystec-
tomy (RC) with comparable perioperative and oncologic out-
comes [1,2]. Recently, the International Robotic Cystectomy 
Consortium collected 2,125 RARC cases and reported that 
the use of intracorporeal urinary diversion (ICUD) increased 
from 9% in 2005 to 97% in 2015 (rate of increase, 11% per 
year) [3].
Recent studies have suggested that RARC improves 
perioperative morbidity and facilitates recovery, which 
would theoretically allow for an earlier initiation of adju-
vant systemic therapies [4,5]. These benefits result from the 
robot-assisted surgery itself, which is, by definition, a mini-
mally invasive technique. Presently, clinicians have been 
debating whether urinary diversion (UD) during RARC is 
best completed extracorporeally or intracorporeally [6-9]. As 
most complications after RARC occur in association with 
UD, ICUD has been investigated as a way to reduce the rate 
of complications [10].
To maximize the advantages of minimally invasive sur-
gery, a total ICUD approach may be a possible alternative. 
It is known that ICUD minimizes evaporative fluid loss; 
reduces the risk of fluid imbalance, estimated blood loss, and 
incisional pain; and restores bowel function more quickly [11]. 
However, despite these potential perioperative benefits, the 
use of ICUD has been criticized because there is uncertainty 
on whether it could be performed during surgery without 
increasing the rate of complications and whether it truly 
benefits the patient [12].
In this multicenter retrospective study, we analyzed the 
complications, perioperative outcomes after RARC with ex-
tracorporeal urinary diversion (ECUD) or ICUD, and onco-
logic outcomes in 362 patients with bladder cancer (BC). 
MATERIALS AND METHODS
This retrospective cross-sectional study included 362 pa-
tients who underwent RARC with bilateral pelvic lymph 
node dissection (PLND) at 6 tertiary institutions between 
2007 and 2017. A total of  6 surgeons from participating 
centers performed the procedures, and all of them were ex-
perts who had performed >30 RARCs. Of them, 4 surgeons 
performed ECUD only and 2 surgeons performed both 










Age (y) 65.1±10.6 65.3±10.5 64.4±11.0 0.477
Sex 0.981a 
   Male 310 (85.6) 238 (85.6) 72 (85.7)
   Female 52 (14.4) 40 (14.4) 12 (14.3)
Body mass index (kg/m2) 23.8±2.9 23.7±3.0 24.2±2.3 0.218
Previous abdominal surgery 46 (12.7) 39 (14.0) 7 (8.3) 0.874
Preoperative chemotherapy 36 (9.9) 27 (9.7) 9 (10.7) 0.243
Type of urinary diversion 0.661a
   Ileal conduit 141 (39.0) 110 (39.6) 31 (36.9)
   Orthotopic bladder substitution 221 (61.0) 168 (60.4) 53 (63.1)
Type of PLND <0.001a,**
   Standard PLND 177 (48.9) 167 (60.1) 10 (11.9)
   Extended PLND 185 (51.1) 111 (39.9) 74 (88.1)
Perioperative outcomes
   Mean operation time (min) 523.232±146.3 510.1±153.5 566.7±113.7 0.002*
   Transfusion rate (%) 19.9 21.2 15.5 0.248
   Mean time to flatus passage (h) 82.1±35.3 85.6±35.6 70.5±25.3 0.001*
   Mean time to oral intake (d) 5.1±2.2 5.3±2.3 4.4±1.3 <0.001**
   Mean time to urinary catheter removal (d) 16.2±18.3 16.5±18.7 15.3±8.5 0.601
   Mean length of hospital stay (d) 21.0±12.3 22.4±12.4 16.6±8.9 <0.001**
Values are presented as mean±standard deviation, number only, or number (%).
ECUD, extracorporeal urinary diversion; ICUD, intracorporeal urinary diversion; PLND, pelvic lymph node dissection.
*p<0.05, **p<0.001. 
a:Pearson chi-square test.
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ICUD and ECUD. The final patient cohort consisted of 278 
patients who underwent ECUD and 84 patients who under-
went ICUD. This study conformed to the standards of the 
Declaration of Helsinki and current ethical guidelines, and 
was approved by the Institutional Review Board of Korea 
University Anam Hospital (approval number: ED10120). The 
need for informed consent was waived by the board.
1. Inclusion and exclusion criteria
The study participants included patients with muscle-
invasive BC or recurrent high grade non muscle invasive 
BC [13]. We excluded patients with stage cM1 disease, prior 
extensive abdominal surgery, complicated surgery or any 
contraindication to the Trendelenburg position. Tumor/
pathologic grade were determined according to the TNM 
staging system and the 2004 World Health Organization/In-
ternational Society of Urologic Pathologists classification of 
papillary urothelial neoplasms, respectively [14]. All research 
and data collection followed the tenets of the Declaration of 
Helsinki.
2. Primary endpoints
The primary endpoints were the complication rates. 
Comparisons were made in accordance with the standard-
ized complications within 90 days of surgery (reported using 
the Clavien–Dindo classification). The specific complications 
that were investigated in each complication group were 
depicted as follows: infectious—urinary tract infection, peri-
tonitis, and fever; respiratory—pneumonia and pulmonary 
embolism; gastrointestinal—ileus (mechanical and paralytic), 
jaundice, and hematochezia; procedure related—transfusion, 
incisional hernia, bowel injury, and lymphocele; genitouri-
nary—hydronephrosis, uretero-ileal anastomosis site stric-
ture/leakage, and scrotal edema; nervous—obturator injury; 
vascular—heart failure. In addition, we selected and com-
pared 2 surgeons who could be representative of each group 
(1 for ECUD and 1 for ICUD). Each surgeon has mastered 
the learning curve by performing >100 RARCs [6]. A total 
of 75 operations (150 cases) were performed by each surgeon 
during the same period. The types of complications were de-
scribed in detail, and statistical differences were analyzed.
3. Secondary endpoints
The secondary endpoints included perioperative param-
eters, recurrence patterns, and oncologic outcomes. Periop-
erative recovery parameters included time to passage of 
Table 2. Overall 90-day complications defined according to a modified Clavien system (grade 1–5)
Complication ECUD (n=278; n, %) ICUD (n=84; n, %) OR 95% CI for OR p-value
Overall complications 171 (61.5) 35 (41.7) 0.447 0.272–0.734 0.001*
Grade 3–5 complications 57 (20.5) 11 (13.1) 0.584 0.291–1.174 0.128
Infectious 43 (15.5) 14 (16.7) 1.093 0.565–2.114 0.791
      Grade 3–5 6 2 1.102 0.218–5.562 0.907
Respiratory 2 (0.7) 1 (1.2) 1.663 0.149–18.567 0.676
      Grade 3–5 0 1 - - 0.068
Gastrointestinal 36 (12.9) 4 (4.8) 0.336 0.116–0.974 0.036*
      Grade 3–5 7 0 - - 0.142
Procedure related 
   (including transfusion)
48 (17.3) 8 (9.5) 0.504 0.228–1.114 0.085
      Grade 3–5 18 4 0.722 0.238–2.196 0.565
Genitourinary 26 (9.4) 2 (2.4) 0.236 0.055–1.018 0.036*
      Grade 3–5 18 1 0.174 0.023–1.323 0.057
Wound related 7 (2.5) 3 (3.6) 1.434 0.363–5.672 0.606
      Grade 3–5 7 1 0.466 0.057–3.846 0.468
Nervous 2 (0.7) 1 (1.2) 1.663 0.149–18.567 0.676
      Grade 3–5 0 0 - - -
Vascular 3 (1.1) 0 (0.0) - - 0.339
      Grade 3–5 1 0 - - 0.579
Miscellaneous 4 (1.4) 2 (2.4) 1.671 0.301–9.286 0.553
      Grade 3–5 0 2 - - 0.010*
The percentages for the complication category do not sum up because 1 patient can have 2 or more complications.





flatus, time to starting oral intake (from liquid diet), time to 
urinary catheter removal, and length of hospital stay. Then, 
the recurrence pattern after RARC with ECUD or ICUD 
was studied. The recurrence type was divided into local and 
distant, and the specific prevalence of recurrence was deter-
mined. Furthermore, for the analysis of oncologic outcomes, 
margin positivity rates and 2-year recurrence-free survival 
(RFS) rates were analyzed. Recurrence was defined as the 
time from cystectomy to local or metastatic recurrence, 
based on histologic or radiologic evidence.
4. Statistical analysis
Continuous variables were expressed as mean±standard 
deviation, and 1-way analysis of variance was used for the 
analysis. Additionally, Pearson chi-square test and Fisher 
exact test were used for analyzing data. The estimated dis-
Table 3. Comparison of complication (defined according to a modified 
Clavien system) rates between ECUD and ICUD performed by 2 expert 







Total complication rate (n, %) 41 (54.7) 31 (41.3) 0.102a
   Grades 1 and 2 31 (41.3) 20 (26.7) 0.058a
   Grades 3–5 10 (13.3) 11 (14.7) 0.814a
Infectious 12 (16.0) 11 (14.7) 0.821a
   Grades 3–5 0 1 1.000b
Respiratory 0 (0.0) 2 (2.7) 0.497b
   Grades 3–5 0 1 1.000b
Gastrointestinal 10 (13.3) 7 (9.3) 0.440a
   Grades 3–5 1 3 0.311b
Genitourinary 12 (16.0) 4 (5.3) 0.028a,*
   Grades 3–5 3 3 1.000b
Wound related 3 (4.0) 3 (4.0) 1.000b
   Grades 3–5 3 3 1.000b
Vascular 2 (2.7) 0 (0.0) 0.497b
   Grades 3–5 1 0 1.000b
Nervous 0 (0.0) 2 (2.7) 0.497b
   Grades 3–5 0 0 -
Miscellaneous 2 (2.7) 2 (2.7) 1.000b
   Grades 3–5 2 0 0.497a
Specific complications were described in the MATERIALS AND METH-
ODS section.
ECUD, extracorporeal urinary diversion; ICUD, intracorporeal urinary 
diversion; RARC, robot-assisted radical cystectomy.
*p<0.05. 
a:Pearson chi-square test, b:Fisher exact test.
Fig. 1. Comparison of perioperative valuables between the extracorporeal urinary diversion (ECUD) and intracorporeal urinary diversion (ICUD) groups. 
(A) Total operation time and console time and (B) recovery parameters (time to flatus, time to oral intake, time to urinary catheter removal, and length of 















































Table 4. Distribution of recurrence locations among patients with re-






Local recurrence 10 (3.6) 2 (2.4)
   Cystectomy bed 4 (1.4) 0 (0.0)
   PLND template 6 (2.2) 2 (2.4)
Distant recurrence 25 (9.0) 7 (8.3)
   Lung 8 (2.9) 1 (1.2)
   Liver 2 (0.7) 1 (1.2)
   Bone 5 (1.8) 2 (2.4)
   Extrapelvic lymph node 2 (0.7) 0 (0.0)
   Peritoneal carcinomatosis 0 (0.0) 2 (2.4)
   Port site 2 (0.7) 0 (0.0)
   Others (brain, adrenal, pancreas, bowel) 1 (0.4) 0 (0.0)
Secondary urothelial carcinoma
   Upper urinary tract 2 (0.7) 0 (0.0)
   Urethra 1 (0.4) 0 (0.0)
Multiple recurrence 2 (0.7) 1 (1.2)
Values are presented as number of recurrence sites (%).
RARC, robot-assisted radical cystectomy; ECUD, extracorporeal urinary 
diversion; ICUD, intracorporeal urinary diversion; PLND, pelvic lymph 
node dissection.
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tribution of RFS was obtained using Kaplan-Meier analysis, 
and the log-rank test was used to compare the Kaplan-Meier 
curves between the groups. All analyses were performed us-
ing SPSS version 20.0 (SPSS Inc., Chicago, IL, USA). Results 
were considered statistically significant if the p-value was 
less than 0.05.
RESULTS
The mean duration of follow-up was 34.7±25.5 months. 
We observed no difference in age, sex, body mass index, inci-
dence of previous abdominal surgery, incidence of neoadju-
vant chemotherapy, and type of UD (ileal conduit or ortho-
topic neobladder substitution) between the 2 groups. In the 
ICUD group, the rate of performing extended PLND was 
significantly higher than that of standard PLND (p<0.001) 
(Table 1).
1. Complications I
In the ECUD group, 171 patients (61.5%) experienced at 
least 1 complication of any grade within 90 days of surgery, 
whereas there were 35 such patients (41.7%) in the ICUD 
group (p=0.001). In the analysis of overall complication and 
major complication rates (grade 3–5), there were no sig-
nificant differences between the 2 groups. The incidence of 
gastrointestinal complications in the ICUD group showed a 
decreasing trend (p=0.036), and there were no major compli-
cations in the ICUD group. The incidence of genitourinary 
complications was also lower (p=0.036) in the ICUD group 
(Table 2). In the analysis of complication rates in the geni-
tourinary tract, there were significant differences between 
the 2 groups (p=0.036). In terms of the type of complication, 
hydronephrosis (20 of 28) was the most common, followed 
by acute kidney injury (5 of 28), urinary stone (2 of 28), and 
bladder neck stricture (1 of 28).
2. Complications II
We performed a head-to-head comparison between 2 
expert surgeons from each group. The total complication 
and major complication rates showed no difference, whereas 
the minor complication rates showed a decreasing trend in 
the ICUD group (ECUD vs. ICUD: 31 [41.3%] vs. 20 [26.7%], 
p=0.058). The urine leakage rates were significantly lower 
(ECUD vs. ICUD: 9 [12.0%] vs. 0 [0.0%], p=0.002) in the ICUD 
group (Table 3).
3. Perioperative parameters
The ICUD group had significantly longer total operation 
time and console time, whereas the postoperative transfusion 
rate showed no difference (21.2% vs. 15.5%, p=0.248). Recovery 
parameters, such as mean time to passage of flatus, start of 
oral intake, and length of hospital stay, were significantly 
shorter in the ICUD group than in the ECUD group (p=0.001, 
p<0.001, and p<0.001, respectively), except for the mean time 
to Foley catheter removal (p=0.601) (Table 1, Fig. 1). 
4. Recurrence patterns
Local/distant recurrence occurred in 10 (3.6%) and 25 
(9.0%) patients in the ECUD group and in 2 (2.4%) and 7 (8.3%) 
patients in the ICUD group, respectively. Concerning both 
types of recurrence, there were no significant differences in 
the recurrence pattern between the 2 groups. Only 3 patients 
experienced recurrence of secondary urothelial carcinoma in 
the upper urinary tract (2 patients) and urethra (1 patient). 
The diversion of recurrence locations is shown in Table 4.
5. Oncologic outcomes
There was no difference in the margin positivity rate 
(p=0.944). In pathologic results, there were no differences 
between the 2 groups in numbers of lymph-node-positive pa-
tients (p=0.523), lymph node density (p=0.127), and pathologic 
tumor stage or nodal stage (p=0.152, p=0.116). The lymph node 
yield was significantly higher in the ICUD group than in 
the ECUD group (29.8±13.6 vs. 15.1±12.1, p<0.001). The 2-year 
RFS showed no significant difference between the 2 groups 
(ECUD vs. ICUD: 83.2% vs. 88.6%, p=0.496) (Table 5).








      Urothelial carcinoma 278 (100.0) 84 (100.0) 1.000
Pathologic tumor stage 0.152a
      T0/Ta/Tis 38 (13.7) 18 (21.4)
      T1/T2 153 (55.0) 38 (45.2)
      T3/T4 87 (31.3) 28 (33.3)
Soft tissue margin positive 7 (2.5) 2 (2.4) 0.944
Lymph node yield 15.1±12.1 29.8±13.6 <0.001*
Pathologic nodal stage 0.116a
      Nx/N0 227 (81.7) 62 (73.8)
      N1/N2/N3 51 (18.3) 22 (26.2)
Recurrence-free survival 
   for 2 years 
83.2 88.6 0.496b
Values are presented as number (%), mean±standard deviation, or a 
percentage only.
ECUD, extracorporeal urinary diversion; ICUD, intracorporeal urinary 
diversion; SD, standard deviation.
*p<0.001. 





The aim of our study was to determine whether ICUD 
has clinical benefits compared with ECUD. Our results sug-
gest that the ICUD approach is beneficial in terms of lower 
complication rates and better perioperative outcomes, as 
indicated by recovery parameters, while maintaining similar 
oncologic outcomes to those of ECUD.
Our study showed a significant advantage of ICUD over 
ECUD for patients with regard to overall complication rates 
and gastrointestinal-related complications. The International 
Robotic Cystectomy Consortium conducted a comparative 
analysis of  ICUD and ECUD. Overall, a trend favoring 
ICUD over ECUD was noted (41% vs. 49%, p=0.05). Gastroin-
testinal complications were significantly lower in the ICUD 
group (p<0.001). Additionally, Bochner et al. [12] reported that 
the most common complications during cystectomy were 
gastrointestinal-, infection-, and wound-related problems in 
their prospective study. Complications related to bowel resec-
tion are undoubtedly one of the biggest problems faced by 
urologists and an important reason for prolonged hospital 
stays. In this regard, the exposure time of the peritoneum to 
external air was proportional to intestinal inflammation and 
oxidative stress response in experimental models using white 
rats. This leads to intestinal paralysis or intestinal obstruc-
tion and delayed restoration of bowel function [15]. Other 
studies comparing laparoscopy and laparotomy in bowel 
surgery have shown a decrease in the levels of cytokines, 
including interleukin (IL)-1, IL-6, and tumor necrosis factor-
alpha, and a reduction in systemic immunosuppression in 
endoscopic surgery as compared with open surgery [15,16].
In our study, the ICUD group showed a decreasing trend 
of genitourinary complications, which consisted mostly of 
urinary leakage or anastomosis site stricture. Furthermore, 
as shown in Table 5, in the analysis of the surgeons who 
overcame the learning curve, lower minor complication rates 
were found in the ICUD group in terms of ureteral com-
plications, whereas the major complication rates were simi-
lar. ECUD requires more ureteral mobilization and longer 
ureteral length, which can result in ureteral redundancy, 
kinking, and devascularization [10]. On the other hand, in 
the ICUD approach, anastomoses are made at the position, 
resulting in less ureter mobilization and tension. In several 
large ICUD series, a low stricture rate of approximately 3% 
was reported [17,18].
Considering the potential advantages of ICUD, patients 
undergoing RC are often older and have several comorbidi-
ties, which are risk factors for increased complications [19]. 
There is evidence that RARC may have an advantage in 
reducing the surgical stress response compared with open 
surgery in older patients or other vulnerable patients [20,21]. 
Reduction in the stress response can be achieved through 
minimal-access surgery [22]. These concepts are in line with 
the benefits of ICUD, such as minimizing the handling time 
of organs in the abdominal cavity, as well as decreasing bow-
el manipulation/exposure and reducing insensible fluid losses 
[23,24]. Our results showed a relatively shorter length of stay 
(days) in patients who underwent ICUD than in those who 
underwent ECUD (16.6±8.9 vs. 22.4±12.4, p<0.001), as well as 
shorter time to passage of flatus and time to starting oral 
intake. Improvements in recovery parameters are especially 
important in elderly patients with comorbidities who under-
go RARC. There is increasing evidence showing that patients 
who are susceptible to the morbidity of major surgery may 
be the ones who will benefit from a robotic approach [20].
In the analysis of recurrence patterns, the overall rates 
of local and distant recurrence did not show any difference 
between the 2 groups. With respect to incidence of distant 
recurrence of solid organs, lung, bone and liver remain the 
most frequent sites and homologous to previous studies [25]. 
The incidence rates of peritoneal carcinomatosis and port 
site recurrence were not significantly different between the 
2 groups. Although no statistically significant differences 
were found, more attention is needed to avoid urine leakage 
when performing the procedure (after removing the speci-
men and transferring it into the endopouch). This is impor-
tant because the follow-up strategy should reflect the risk of 
extravesical recurrence [26], and this type of recurrence was 
observed in the ECUD group only.
Despite several potential perioperative benefits, the use 
of RARC has been criticized owing to the paucity of reports 
about a few oncologic concerns. According to the data avail-
able to date, RARC can implement adequate PLND in terms 
of its territory and yield, and has an acceptable positive sur-
gical margin (PSM) rate. In addition, it is possible to avoid 
urine leakage or inadvertent bladder injury and safely per-
form the surgery while adhering to the oncologic principles. 
Furthermore, it showed similar results to those of an open 
series in patients with mostly T3 or higher stages. In our 
study, the PSM (p=0.944) and lymph-node-related factors 
did not differ, except that the lymph node yield and short-
term RFS (p=0.496) did not show inferior results to those of 
ECUD. Although ICUD remains a complex procedure, the 
outcomes of this study agree with those of previous stud-
ies, thereby demonstrating the potential benefits of ICUD 
after RARC. This will contribute to ICUD gaining popular-
ity as a viable alternative to ECUD. Theoretically, there is 
no difference in the oncologic outcome between ECUD and 
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ICUD. Nevertheless, the reason why we evaluated the onco-
logic outcome is that there is a slight procedural difference 
between the 2 methods after a cystectomy. In the case of 
ICUD, the time during which the specimen stays inside the 
body is inevitably longer, according to the surgical principle. 
Accordingly, precaution is needed because of the possibilities 
of local tumor spillage and urine leakage even after remov-
ing the specimen.
There are some limitations in this study. First, the medi-
cal records of  consecutive patients were retrospectively 
reviewed. The number and timing of operations performed 
in each surgeon are different, and this may have affected 
the outcome of our study. Therefore, this study is limited by 
biases such as lack of randomization, patient selection bias. 
Better designed research would be needed in the future. 
CONCLUSIONS
In this multicenter trial, there were decreasing trends 
in overall, gastrointestinal, and genitourinary complications 
in the ICUD group. The ICUD group showed significantly 
improved recovery parameters compared with the ECUD 
group. Analysis of oncologic outcomes at intermediate-term 
follow-up revealed no differences in the PSM rate, recur-
rence pattern, or RFS between the 2 UD techniques. In the 
future, the results of prospective, randomized controlled tri-
als between RARC and open RC are awaited to confirm the 
current findings.
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